Endocrine and neuroendocrine tumours
Invited discussant abstracts 420PD, 421PD, 422PD and 423PD
Date
10 Oct 2016Session
Endocrine and neuroendocrine tumoursPresenters
Rocio Garcia-CarboneroAuthors
R. Garcia-CarboneroAuthor affiliations
- Medical Oncology Department, Hospital Universitario Virgen del Rocio, Madrid/ES
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
3586 - NETTER-1 phase III in patients with midgut neuroendocrine tumors treated with 177Lu-dotatate: Efficacy, safety, QoL results and subgroup analysis
Presenter: Jonathan Strosberg
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
3579 - Impact of prior therapies on everolimus treatment in the subgroup of patients with advanced lung neuroendocrine tumors (NET) in the RADIANT-4 trial
Presenter: Roberto Buzzoni
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
3964 - Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome
Presenter: Matthew Kulke
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
2491 - Phase I, open-label, dose-escalation study of SNX-5422 plus everolimus in neuroendocrine tumors (NETs)
Presenter: Martin Gutierrez
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
2726 - Prevalence of gastroenteropancreatic and lung neuroendocrine tumours in the European Union
Presenter: Aurore Bergamasco
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
3150 - Multicentre evaluation of the role of Gallium DOTA-PET (GaPET) imaging in well differentiated bronchial carcinoids (BC): Impact on patients' (pts) management
Presenter: Angela Lamarca
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
1222 - A population based analysis of outcome of chemotherapy for metastatic pulmonary large cell neuroendocrine carcinomas: does the regimen matter?
Presenter: Jules Derks
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
2033 - Pediatric, adolescent and young adult (PAYA) thyroid carcinoma harbors frequent and diverse targetable genomic alterations including kinase fusions
Presenter: Pierre Vanden Borre
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
2396 - Damaging germline variants in TSC2 are frequently found among nonsyndromic patients with gastroenteropancreatic (GEP) neuroendocrine tumors (NETs)
Presenter: Rudinei Linck
Session: Endocrine and neuroendocrine tumours
Resources:
Abstract
Invited discussant abstracts 427PD and 428PD
Presenter: Xavier Matias-Guiu
Session: Endocrine and neuroendocrine tumours
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.